Skip to main content

Positron Corporation Secures Agreement to Sell and Rent Eight NeuSight PET-CT Scanners

Written by Customer Service on . Posted in Public Companies.

Niagara Falls, NY, Jan. 24, 2025 (GLOBE NEWSWIRE) — Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company specializing in PET and PET-CT imaging systems and clinical services, is pleased to announce the sale of four and rental of four NeuSight PET-CT 64-slice scanners to a prominent, established provider of advanced diagnostics and treatment for cardiovascular disease. This achievement highlights Positron’s commitment to providing innovative imaging solutions that enable healthcare providers to elevate patient care and achieve superior clinical outcomes.

The NeuSight PET-CT is designed to transform cardiac PET imaging by combining exceptional performance, advanced technology, and unmatched value. Renowned for its top-tier performance and international success, the NeuSight PET-CT stands out with its patient-centered design, featuring a spacious 72 cm gantry for enhanced comfort and high-sensitivity acquisition technology that minimizes radiation exposure for both patients and technicians. With the smallest footprint and lightest weight among PET-CT systems, it offers superior imaging capabilities while optimizing space utilization, making it an ideal solution for modern healthcare facilities.

As a cost-effective and innovative system, the NeuSight PET-CT excels in both cardiology and oncology clinical studies. Its advanced data acquisition and identification technology enable faster and more precise scans, improving diagnostic accuracy. Offering both anatomic and functional imaging, the NeuSight PET-CT supports a wide range of molecular imaging applications, including heart, tumor, and brain studies, showcasing its versatility and commitment to advancing medical diagnostics.

Adel Abdullah, President of Positron, stated, “We are thrilled to collaborate with such a premier  cardiovascular practice dedicated to providing the highest standard of cardiac care. We are also delighted to offer our comprehensive rental program and are excited to support the practice’s continued growth and success.” Mr. Abdullah added, “Positron provides physicians with the best in cardiac PET and PET-CT imaging to support their patients needs. Our clinical team and network of industry-leading physicians offer expert training and support to ensure customers maximize the benefits of our Attrius PET and NeuSight PET-CT systems, including advanced data quantification and CFR applications. Positron’s solutions blend cutting-edge technology with cost-effectiveness, making them ideal for nuclear imaging practices.”

About Positron Corporation
Positron Corporation is a medical technology company that co-develops, manufactures, and sells  state-of-the-art PET and PET-CT imaging systems and clinical services to nuclear medicine healthcare providers throughout North America.

Positron specializes in the field of cardiac Positron Emission Tomography (PET) imaging, the gold standard in cardiac diagnostics. Positron’s innovative PET/PET-CT technologies, clinical services and practice solutions enables healthcare providers to accurately diagnose coronary artery disease and improve patient outcomes while practicing cost effective medicine.

Positron’s Attrius® PET and NeuSight PET-CT imaging systems and distinct market position are substantial advantages unique to Positron that will facilitate the adoption of cardiac PET and the growth of the nuclear imaging market. Positron will soon offer a state-of-the-art PET-CT 4D molecular imaging device in the Affinity PET-CT 4D 64-Slice. Positron’s PET-CT(s) will enable nuclear cardiologists to utilize the full capabilities of molecular imaging and nuclear medicine. Positron’s PET-CT systems will also enable the Company to fully service and meet the demands of the vast oncology imaging segment of nuclear medicine. 

Positron is committed to expanding the cardiac and oncology PET modality by delivering the best technology and value to imaging specialists and will continue to advance its technology through its co-developer, supplier, and R&D venture with Shenyang Intelligent Neuclear Technology Co. a subsidiary of Neusoft Medical Systems.  

Please visit the Company’s website at: www.positron.com

Forward-Looking Statements                                        
This press release contains statements which may constitute “forward-looking statements” within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Positron Corporation, and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results even if new information becomes available in the future.

FOR FURTHER INFORMATION, please visit the company’s website at www.positron.com, or contact: investor@positron.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.